Tipiracil

Thymidine Phosphorylase Inhibitor

Key facts

Tipiracil is an ofp drug in the Thymidine Phosphorylase Inhibitor class catalogued in DrugCentral. It was first approved by the PMDA in 2014. Its mechanism of action is classified as Thymidine Phosphorylase Inhibitors. DrugCentral lists 2 molecular targets, including deoA and TYMP. Recorded indications include Malignant tumor of colon and Malignant tumor of stomach.

• Approval status: ofp (first approved 2014 by the PMDA).
• Drug class: Thymidine Phosphorylase Inhibitor.
• Mechanism of action: Thymidine Phosphorylase Inhibitors.
• Molecular targets: deoA and TYMP (2 listed in DrugCentral).
• Indications: Malignant tumor of colon and Malignant tumor of stomach.
• Molecular formula: C9H11ClN4O2; molecular weight 242.66 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Malignant tumor of colon
• Malignant tumor of stomach

Mechanism & targets

• Mechanism of action (MoA): Thymidine Phosphorylase Inhibitors
• Established pharmacologic class: Thymidine Phosphorylase Inhibitor

Molecular targets (2)

Target	Gene	Action	Activity
Thymidine phosphorylase	deoA	unknown	IC50 7.70
Thymidine phosphorylase	TYMP	inhibitor	IC50 7.70

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2015-09-22	FDA	—	TAIHO ONCOLOGY INC
2014-03-24	PMDA	—	Taiho Pharmaceutical Co., Ltd.

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Therapy partial responder	76.5

Chemical structure

• Molecular formula: C₉H₁₁ClN₄O₂
• Molecular weight: 242.66 g/mol
• CAS number: 183204-74-2
• InChIKey: QQHMKNYGKVVGCZ-UHFFFAOYSA-N
• PubChem CID: 6323266

ClC1=C(CN2CCCC2=N)NC(=O)NC1=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Tipiracil used for?

DrugCentral lists the following indications for Tipiracil: Malignant tumor of colon and Malignant tumor of stomach.

How does Tipiracil work?

Tipiracil is classified as Thymidine Phosphorylase Inhibitors; its molecular targets in DrugCentral include deoA and TYMP (inhibitor).

When was Tipiracil first approved?

Tipiracil was first approved by the PMDA in 2014.

What drug class does Tipiracil belong to?

Tipiracil is in the Thymidine Phosphorylase Inhibitor class.

What is the chemical formula of Tipiracil?

Tipiracil has the molecular formula C9H11ClN4O2 and a molecular weight of 242.66 g/mol.

Sources

• DrugCentral drug card 4893 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL235668 — compound record and bioactivity
• PubChem CID 6323266 — chemical identifiers
• DrugBank DB09343 — drug record
• FDA UNII NGO10K751P — substance identity
• DailyMed: FDA labels for Tipiracil — current prescribing information (label search)
• UniProt P19971 (TYMP) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.